Bayer: continuing growth momentum

Bayer2012 was a very successful year for the Bayer Group. "We continued to grow dynamically and achieved our targets for the Group. All the subgroups posted gains in sales and earnings before special items," said Bayer CEO Dr. Marijn Dekkers at the Financial News Conference in Leverkusen on Thursday. The life-science businesses registered particularly rapid growth and were strengthened by further progress in the innovation pipeline. Moreover, Bayer sharply expanded business in the emerging markets. Dekkers expressed his confidence for the company’s future development: "We expect to continue our record development in 2013 and beyond."

Sales of the Bayer Group grew by 8.8 percent in 2012, to EUR 39,760 million (2011: EUR 36,528 million). "Sales thus reached the highest level in our company’s 150-year history," said Dekkers. Adjusted for currency and portfolio effects (Fx & portfolio adj.), sales were up by 5.3 percent. The gain in the emerging markets, at 7.4 percent (Fx & portfolio adj.), was twice as large as in the industrialized countries. "In other words, our strategic focus on these markets of the future - and the investments we are making there - are paying off," Dekkers remarked.

EBIT declined by 4.6 percent to EUR 3,960 million (2011: EUR 4,149 million). Special items totaled minus EUR 1,711 million (2011: minus EUR 876 million). They included EUR 1,186 million in litigation expenses in connection with the Yasmin™/YAZ™ line of oral contraceptives. Of this figure, EUR 455 million was taken in the fourth quarter of 2012, primarily in connection with further provisions for the settlement in the United States of venous clot injury claims of which Bayer is currently aware and anticipated future claims. Further special charges for the year overall included EUR 396 million for restructuring measures and EUR 289 million for impairment of intangible assets. An offsetting effect came from gains of EUR 158 million from divestitures and EUR 114 million in adjustments of benefit entitlements.

EBIT before special items increased by 12.9 percent to EUR 5,671 million (2011: EUR 5,025 million). EBITDA before special items rose by 8.8 percent to EUR 8,284 million (2011: EUR 7,613 million). Contributing to this were a good business performance and savings from the efficiency program successfully completed in 2012. Earnings also benefited from positive currency effects totaling about EUR 400 million. Net income declined slightly by 1.0 percent to EUR 2,446 million (2011: EUR 2,470 million). Core earnings per share, however, improved by 10.8 percent to EUR 5.35 (2011: EUR 4.83).

Gross cash flow fell by 11.1 percent to EUR 4,599 million (2011: EUR 5,172 million), while net cash flow declined by 10.4 percent to EUR 4,532 million (2011: EUR 5,060 million). Net financial debt was level with December 31, 2011, at EUR 7.0 billion. "This included additional funding of EUR 1.0 billion for our pension fund in the fourth quarter of 2012," explained Chief Financial Officer Werner Baumann. "Our outstanding financial liabilities have a balanced maturity structure. We therefore intend to continue making repayments in the coming years entirely from our available liquidity and current cash flows," Baumann added.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries.

Most Popular Now

Roche launches imCORE, a global network of cancer …

Roche (SIX: RO, ROG; OTCQX: RHHBY) has launched the global cancer immunotherapy Centers of Research Excellence (imCORE™) Network. This network brings together many of the...

Read more

15th Annual eyeforpharma Philadelphia 2017

20 - 21 April 2017, Philadelphia, USA. It's eyeforpharma Philadelphia's 15th year; already the largest, most senior and most influential forum for commercial pharma exec...

Read more

Merck wins R&D 100 Award for top invention

Merck, a leading science and technology company, received a prestigious R&D 100 Award for its Sanger Arrayed Lentiviral CRISPR Libraries - the first of its kind CRISPR li...

Read more

Benzodiazepine and related drug use increases hip …

The use of benzodiazepines and related drugs increases the risk of hip fracture by 43% in persons with Alzheimer's disease, according to a new study from the University o...

Read more

Among antidementia drugs, memantine is associated …

A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia. The use of...

Read more

World of viruses uncovered

A groundbreaking study of the virosphere of the most populous animals - those without backbones such as insects, spiders and worms and that live around our houses - has u...

Read more

Boehringer Ingelheim and China Southeast Universit…

Boehringer Ingelheim and China Southeast University Institute of Life Sciences have announced the start of a joint research project to develop new treatment approaches fo...

Read more

Smart patch releases blood thinners as needed

An interdisciplinary team of researchers has developed a smart patch designed to monitor a patient's blood and release blood-thinning drugs as needed to prevent the occur...

Read more

Novartis acquires Selexys Pharmaceuticals Corporat…

Novartis today announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammator...

Read more

Novo Nordisk expands programme to reach 20,000 chi…

Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children wi...

Read more

IBM and Pfizer to accelerate immuno-oncology resea…

IBM (NYSE: IBM) Watson Health and Pfizer Inc. (NYSE: PFE) have announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's resea...

Read more

Greater efforts are needed to encourage patients t…

In a review of published studies addressing patients' perceptions and factors influencing their reporting of adverse drug reactions, most patients were not aware of repor...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]